<unk>  is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase survival. ,<unk>  has not been studied in people with a left ventricular ejection fraction value of ≤ 50% normal, a prior history of congestive heart failure, or conditions that could impair left ventricular function like uncontrolled hypertension, recent heart attacks, or serious cardiac arrhythmia. Caution should be used combining<unk>  with an anthracycline. There is also no safety data available for use of<unk>  in combination with doxorubicin. Women of child-bearing age should use contraception while taking<unk> ; it may damage the fetus in pregnant women, and it may be secreted in breast milk.
Pertuzumab
Gatipotuzumab
Theralizumab
Caplacizumab
Elotuzumab
Idarucizumab
Risankizumab
Alemtuzumab